This US News & World Report story reports on a small study measuring brain activity, but makes it sound like a major step forward. The specifics of the study are glossed over, no connection is made between brain activity and clinical symptoms or outcomes, and there’s no mention of cost or potential harms. In addition, the story relies on a news release from the research university where the study was done and canned quotes from the study author.
People coming into emergency rooms with psychotic symptoms is a common enough occurrence that there are established treatment guidelines. The symptoms may be caused by any number of things, such as drugs of abuse or medications, as well as mental illness or other medical conditions. To manage patients, antipsychotic drugs are often administered. These drugs come with a raft of side effects, so a treatment that could quell symptoms quickly with fewer side effects would certainly be useful.
There is some evidence that cannabidiol might be helpful for acute psychosis, though much more is needed. News coverage of current research can be worthwhile if it puts new findings into context.
The article did not mention costs of cannabidiol.
Internet sources of cannabidiol can cost 4 to 20 cents per milligram, though the dosage and quality of these products is not regulated. The study used a 600 mg dose, so the cost would be $24-$120 for a single dose. The FDA-approved version of the drug (approved for childhood epilepsy, not psychosis) runs $32,000 a year, although insurance may cover some of that cost.
The headline claims that CBD reduces symptoms of psychosis, but never provides any evidence that is true.
We’re told that people with psychotic symptoms who received cannabidiol “showed decreased abnormal activity” in MRI scans of brain activity. The very next sentence states: “These results suggest that CBD can help re-adjust brain function to normallevels.”
Did normal “brain function” mean no more psychosis? We’re not told. More importantly, brain activity is not a symptom.
The article made no mention of possible side effects of cannabidiol, which can include tiredness, diarrhea, and changes of appetite/weight. These effects are considered mild, but we maintain that the potential for untoward effects deserve consideration.
The article does not help readers evaluate the study’s strengths or weaknesses. This was a randomized clinical trial (a strength) done in 33 subjects (a small enough number to be a weakness). Additionally, there is no mention of the timing between administration of the study drug (just a one-time dose) and measurement of brain activity (at baseline or follow-up).
More importantly, the article does not help readers how abnormal brain activity relates to overt (or obvious) psychotic symptoms — or that normalizing brain activity has clinical significant effects.
Further, there is no mention as to why participants “experiencing psychotic symptoms but not yet diagnosed with psychosis” were chosen. In the larger clinical trial by the same investigator, the CBD compound was given in individuals with overt psychosis. The reason for the selection of this study population is unclear, as is the duration of therapy.
No disease-mongering here, although more could have been said about the frequency of psychosis and which disorders it’s most commonly associated with.
The only source quoted in the article was a study author.
An independent perspective is crucial to convey the significance of this study and its findings.
The article does mention older antipsychotic drugs, but does not compare their effects on the main outcome — abnormal brain activity. One might expect a comparison of side effects between traditional antipsychotics and cannabidiol, which is likely where the latter would seem advantageous (if the therapeutic effects are equivalent, which is not at all clear).
We’ll give this a satisfactory rating because the article mentions the FDA approval of the drug for epilepsy, which implies that its commercially available. But it’s not clear if the dosing would be similar.
The story indicates there is previous research that shows a connection between CBD and how it affects psychosis.
The article appears to rely heavily on this King’s College London news release.
This US News & World Report story reports on a small study measuring brain activity, but makes it sound like a major step forward. The specifics of the study are glossed over, no connection is made between brain activity and clinical symptoms or outcomes, and there’s no mention of cost or potential harms. In addition, the story relies on a news release from the research university where the study was done and canned quotes from the study author.
People coming into emergency rooms with psychotic symptoms is a common enough occurrence that there are established treatment guidelines. The symptoms may be caused by any number of things, such as drugs of abuse or medications, as well as mental illness or other medical conditions. To manage patients, antipsychotic drugs are often administered. These drugs come with a raft of side effects, so a treatment that could quell symptoms quickly with fewer side effects would certainly be useful.
There is some evidence that cannabidiol might be helpful for acute psychosis, though much more is needed. News coverage of current research can be worthwhile if it puts new findings into context.
The article did not mention costs of cannabidiol.
Internet sources of cannabidiol can cost 4 to 20 cents per milligram, though the dosage and quality of these products is not regulated. The study used a 600 mg dose, so the cost would be $24-$120 for a single dose. The FDA-approved version of the drug (approved for childhood epilepsy, not psychosis) runs $32,000 a year, although insurance may cover some of that cost.
The headline claims that CBD reduces symptoms of psychosis, but never provides any evidence that is true.
We’re told that people with psychotic symptoms who received cannabidiol “showed decreased abnormal activity” in MRI scans of brain activity. The very next sentence states: “These results suggest that CBD can help re-adjust brain function to normal levels.”
Did normal “brain function” mean no more psychosis? We’re not told. More importantly, brain activity is not a symptom.
The article made no mention of possible side effects of cannabidiol, which can include tiredness, diarrhea, and changes of appetite/weight. These effects are considered mild, but we maintain that the potential for untoward effects deserve consideration.
The article does not help readers evaluate the study’s strengths or weaknesses. This was a randomized clinical trial (a strength) done in 33 subjects (a small enough number to be a weakness). Additionally, there is no mention of the timing between administration of the study drug (just a one-time dose) and measurement of brain activity (at baseline or follow-up).
More importantly, the article does not help readers how abnormal brain activity relates to overt (or obvious) psychotic symptoms — or that normalizing brain activity has clinical significant effects.
Further, there is no mention as to why participants “experiencing psychotic symptoms but not yet diagnosed with psychosis” were chosen. In the larger clinical trial by the same investigator, the CBD compound was given in individuals with overt psychosis. The reason for the selection of this study population is unclear, as is the duration of therapy.
No disease-mongering here, although more could have been said about the frequency of psychosis and which disorders it’s most commonly associated with.
The only source quoted in the article was a study author.
An independent perspective is crucial to convey the significance of this study and its findings.
The article does mention older antipsychotic drugs, but does not compare their effects on the main outcome — abnormal brain activity. One might expect a comparison of side effects between traditional antipsychotics and cannabidiol, which is likely where the latter would seem advantageous (if the therapeutic effects are equivalent, which is not at all clear).
We’ll give this a satisfactory rating because the article mentions the FDA approval of the drug for epilepsy, which implies that its commercially available. But it’s not clear if the dosing would be similar.
The story indicates there is previous research that shows a connection between CBD and how it affects psychosis.
The article appears to rely heavily on this King’s College London news release.
Systematic, Criteria-Driven
Shout out to @HealthNewsRevu (that has had such an impact on how journalists report industry-sponsored medical misinformation) from @ShannonBrownlee and @JeanneLenzer1 on today's Viral Misinformation webinar
#COVID19
Don’t believe everything you hear, kids.
“What in the world justifies rushing a 348-word story to publication on a Sunday without doing extra research and reporting? Just because a scientist said it? COVID-19 journalism that devolves to that level of dreck is dangerous.”
🔥👇 https://twitter.com/garyschwitzer/status/1268175065478320131
.@Reuters: why rush to publish a 348-word story claiming #COVID19 is losing potency without doing extra research and reporting? Just because a scientist said it? #COVID19 journalism that devolves to that level of dreck is dangerous. https://www.healthnewsreview.org/2020/06/reuters-report-is-another-classic-case-study-in-how-not-to-cover-covid-19-news/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like